Silence Therapeutics PLC(US:SLN)2026-03-05 12:40Financial Performance - Silence Therapeutics reported a net loss of $88.6 million for the year ended December 31, 2025, compared to a net loss of $45.3 million for 2024, representing a 95.5% increase in losses [10]. - Collaboration revenue decreased to $0.6 million in 2025 from $43.3 million in 2024, primarily due to the conclusion of the Hansoh collaboration and a $17.4 million decrease in revenue from the AstraZeneca collaboration [10]. - Research and development (R&D) expenses were $67.8 million for 2025, slightly down from $67.9 million in 2024 [10]. - General and administrative (G&A) expenses decreased to $22.3 million in 2025 from $26.9 million in 2024, attributed to reduced SEC reporting requirements and cost-saving initiatives [10]. - Cash, cash equivalents, and short-term investments totaled $85.1 million as of December 31, 2025, down from $121.3 million in 2024 [10]. - Total outstanding shares were 141,701,848 as of December 31, 2025, compared to 141,674,074 in 2024 [10]. Clinical Development - The topline results for the Phase 2 SANRECO trial of divesiran are now anticipated in the third quarter of 2026, accelerated from the previously expected second half of 2026 due to faster enrollment [3]. - Silence Therapeutics is set to regain exclusive rights to SLN312 after AstraZeneca decided not to pursue further development beyond Phase 1 [7]. - The company generated promising preclinical data for two new mRNAi GOLD™ platform programs, SLN365 and SLN098, with additional data expected in the second quarter of 2026 [10]. Leadership Changes - The company is currently searching for a new CEO following the departure of the former CEO in December 2025 [10].